AIImpactLab
9 impact clustersWork & marketsCognition & learningTechnical failuresPrivacySecurityEnvironmentLaw & informationSocial good & healthSystemic risk
Search the evidence

Find the signal.

Search titles, impact clusters, countries, organizations and the full text of every analysis.

7 stories found

A patient and clinician face a polished medical AI prism while trust and safety evidence remain obscured behind a frosted clinical wall.
Social good & healthGlobal+3 clusters01

Medical AI studies measure satisfaction far more than trust or safety

A Nature Health systematic review of 330 medical-AI studies found that patient factors are rarely integrated across the full AI lifecycle and are heavily concentrated in late validation. Among the papers reviewed, 70.6 percent assessed patient satisfaction and 69.4 percent perceived benefits, but only 16.7 percent examined trust and 10.9 percent safety. Patient factors were assessed during validation in 89.4 percent of cases, while only 3.9 percent incorporated them during design and development. The analysis covers reported studies rather than new patient-level data, and the included research spans different applications and methods, so the percentages should not be treated as a single performance score for medical AI. The pattern is still consequential. A patient can report a satisfying interaction without understanding the system, trusting the institution that uses it, or being protected from error and harm. If trust, safety, usability, adherence, privacy, and patient characteristics arrive only after a model is built, the product may optimize for a population and workflow that never existed outside the laboratory.

5 min
A wall of 1,357 medical-device approval tiles narrows to three illuminated patient-outcome records beside an empty hospital evidence chart.
Social good & healthUnited States · Global implications+3 clusters02

Only three of 1,357 FDA-authorized AI medical devices were evaluated on patient outcomes

A PLOS Digital Health evidence census linked the FDA's 1,357 authorized AI and machine-learning medical devices through December 5, 2025 to prospective trials and publications. Thirty-four devices were linked to registered prospective trials, 12 had posted results, 12 had peer-reviewed publications, and only three evaluated patient-centered outcomes such as mortality, morbidity, or readmission. The review does not show that the remaining devices are ineffective; it shows that authorization and benchmark performance rarely answer the outcome question patients care about most. With 78 percent of the devices concentrated in radiology and vulnerable populations often excluded from studies, the validation gap can travel through hospitals and across countries long before durable benefit or equitable performance is known.

5 min
An ordinary chest CT reveals a small illuminated esophageal lesion while an AI triage path directs the patient toward confirmatory endoscopy.
Social good & healthChina and international validation sites+4 clusters03

AI found hidden esophageal cancers in CT scans patients already had

A multicenter Nature Medicine study reports that an AI system called EAGLE can identify esophageal cancer and precancerous lesions in noncontrast chest CT scans that were not acquired specifically for the esophagus. The model was trained on 6,813 patients and validated across 12 centers in three countries involving 80,612 patients. In external cohorts totaling 11,466 people, it reached 90.0 percent sensitivity for cancer and 98.5 percent specificity, while sensitivity for precancerous lesions was lower at 52.5 percent. A calibration cohort of 35,402 patients reduced false positives by 72.7 percent while preserving sensitivity. In a prospective hospital cohort of 17,446 patients, 38 of 90 positive predictions were true positives, producing a 42.2 percent positive predictive value and 87.8 percent sensitivity for cancer. A real-world low-dose screening cohort of 10,959 people reported 99.94 percent specificity. The opportunity is unusually practical: use scans already being performed to identify people who should receive confirmatory endoscopy. But the strongest efficiency claims remain modeled. Simulations suggested triage could triple detection, reduce diagnostic time by 70.4 percent, and lower costs in seven of eight countries. Those are not randomized outcomes or evidence of reduced mortality. Most data came from China, follow-up was under two years, endoscopy adherence was limited, and broader validation is needed for different disease patterns. EAGLE may make existing imaging more valuable. It has not yet proved that population deployment improves survival or avoids harmful overdiagnosis.

10 min
A federal AI and supercomputing hub connecting health data, drug discovery, infrastructure materials, and scientific research.
Social good & healthUnited States+3 clusters04

A $5 billion federal push links AI to health, infrastructure and science

The U.S. government has committed more than $5 billion to expand the Genesis Mission, a multi-agency effort that combines federal datasets, Department of Energy supercomputers, research facilities, and AI tools. More than 15 agencies and 278 selected projects will target problems including chronic disease, pediatric cancer, drug discovery, resilient building materials, transportation maintenance, energy, manufacturing, agriculture, and national security.

3 min
A wearable bioelectronic patch linking biosensing, an AI decision node, human oversight, and controlled therapy in a closed loop.
Social good & healthGlobal+2 clusters05

Gao et al., “AI-powered closed-loop wearable bioelectronics for personalized and autonomous healthcare”

A Nature Sensors review argues that AI-powered closed-loop wearables could move healthcare devices beyond passive data collection by connecting continuous biosensing directly to AI-guided decisions and therapeutic intervention. The authors emphasize that clinical value depends on the coordinated system—sensing, control, treatment, and human oversight—not any component alone. Long-term interface stability, robust control, transparent safety mechanisms, and evidence of patient benefit remain prerequisites for scalable use.

3 min
Cognition & learningGlobal+2 clusters06

Souei et al., “Artificial intelligence in deep brain stimulation for movement disorders: a systematic review and technology readiness assessment”

Researchers reviewed 239 peer-reviewed studies on AI-supported deep-brain stimulation and found a pronounced gap between reported algorithmic performance and clinical readiness. External validation remained rare, evaluations were predominantly retrospective and single-centre, and more than one-quarter of studies used small, high-dimensional datasets with elevated overfitting risk; most systems therefore remained at early-to-intermediate technology-readiness levels.

2 min
A conventional microscope with a compact motorized stage scans a bone-marrow slide and routes candidate-cell evidence to a gloved clinical reviewer.
Social good & healthUnited States and Global+3 clusters07

A low-cost self-driving microscope screens bone marrow slides for acute leukemia

A Nature Communications study presents ALLocate, a low-cost AI-powered plugin that turns a conventional microscope into a self-driving screening system for acute leukemia. The system automatically selects useful bone-marrow regions, detects cells, and produces a slide-level result without a whole-slide scanner. Researchers trained and evaluated it with more than 11,000 annotated regions and 130,000 annotated cells, then used independent multi-institutional cohorts that included 165 physical bone-marrow smear slides. Reported performance exceeded 0.99 AUROC for region selection, reached 0.90 mean average precision for cell detection, and achieved 88 percent accuracy for diagnosis on glass slides. That combination could make automated screening more accessible where scanners and specialist expertise are scarce. It does not support an autonomous final diagnosis. An 88 percent result leaves clinically important errors, and the study does not erase the need for population-specific validation, slide-quality checks, calibration, human confirmation, and escalation to a pathologist. The strongest deployment is a lower-cost bridge to expertise, not a substitute for it.

5 min